The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127. https://doi.org/10.1056/NEJMOA2204233/

Article  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. https://doi.org/10.1056/NEJMOA2024816/

Article  PubMed  CAS  Google Scholar 

Navaneethan SD, Zoungas S, Caramori ML et al (2023) Diabetes management in chronic kidney disease: Synopsis of the KDIGO 2022 clinical practice Guideline Update. Ann Intern Med 176:381–387. https://doi.org/10.7326/M22-2904

Article  PubMed  Google Scholar 

Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389:2239–2251. https://doi.org/10.1016/S0140-6736(17)30058-2

Article  PubMed  CAS  Google Scholar 

Thomas MC, Cooper ME, Zimmet P (2015) Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2015 122 12:73–81. https://doi.org/10.1038/nrneph.2015.173

Article  CAS  Google Scholar 

Dennis JM, Henley WE, McGovern AP et al (2019) Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010–2017. Diabetes Obes Metab 21:1576–1584. https://doi.org/10.1111/DOM.13687

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e074068. https://doi.org/10.1136/BMJ-2022-074068

Article  PubMed  PubMed Central  Google Scholar 

Tsai WC, Hsu SP, Chiu YL et al (2022) Original research: Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open 12:60655. https://doi.org/10.1136/BMJOPEN-2021-060655

Article  Google Scholar 

Kaze AD, Zhuo M, Kim SC et al (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21:47. https://doi.org/10.1186/S12933-022-01476-X

Article  PubMed  PubMed Central  CAS  Google Scholar 

D’Andrea E, Wexler DJ, Kim SC et al (2023) Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med 183:242–254. https://doi.org/10.1001/JAMAINTERNMED.2022.6664

Article  PubMed  PubMed Central  Google Scholar 

Fralick M, MacFadden DR (2020) A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diabetes Obes Metab 22:755–758. https://doi.org/10.1111/DOM.13959

Article  PubMed  CAS  Google Scholar 

Cao H, Rao X, Jia J et al (2023) Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 60:325–335. https://doi.org/10.1007/S00592-022-01989-7

Article  PubMed  CAS  Google Scholar 

Offurum A, Wagner L-AA, Gooden T (2016) Adverse safety events in patients with Chronic Kidney Disease (CKD). Expert Opin Drug Saf 15:1597–1607. https://doi.org/10.1080/14740338.2016.1236909

Article  PubMed  Google Scholar 

Gupta R, Alcantara R, Popli T et al (2021) Myopathy associated with statins and SGLT2 - A review of literature. Curr Probl Cardiol 46:100765. https://doi.org/10.1016/J.CPCARDIOL.2020.100765

Article  PubMed  Google Scholar 

Stella M, Biassoni E, Fiorillo C et al (2022) A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors. Neurol Sci 43:4567–4570. https://doi.org/10.1007/S10072-022-06046-3

Article  PubMed  Google Scholar 

Tournadre A (2020) Statins, myalgia, and rhabdomyolysis. Jt bone Spine 87:37–42. https://doi.org/10.1016/j.jbspin.2019.01.018

Article  CAS  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/BMJ.N71

Article  PubMed  PubMed Central  Google Scholar 

Higgins J, James Thomas, Chandler J et al (2022) Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 The Cochrane Collaboration. https://www.training.cochrane.org/handbook/current. Accessed 9 May 2024

Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926

Article  PubMed  PubMed Central  Google Scholar 

GRADEpro GDT (2022) GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, https://www.gradepro.org/. Accessed 14 Apr 2024

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129–139. https://doi.org/10.1056/NEJMOA2030186

Article  PubMed  CAS  Google Scholar 

Potier L, Mohammedi K, Velho G, Roussel R (2021) SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. Cardiovasc Diabetol 20:107. https://doi.org/10.1186/S12933-021-01301-X

Article  PubMed  PubMed Central  CAS  Google Scholar 

Milder TY, Stocker SL, Day RO, Greenfield JR (2020) Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf 43:1211–1221. https://doi.org/10.1007/S40264-020-01010-6

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fitchett D (2019) A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab 21 Suppl 2:34–42. https://doi.org/10.1111/DOM.13611

Article  Google Scholar 

Ishigami J, Grams ME, Chang AR et al (2017) CKD and risk for hospitalization with infection: the atherosclerosis risk in communities (ARIC) Study. Am J Kidney Dis 69:752–761. https://doi.org/10.1053/j.ajkd.2016.09.018

Article  PubMed  Google Scholar 

Wiegley N, Nikolai So P (2022) Sodium-Glucose cotransporter 2 inhibitors and urinary tract infection: Is there room for real concern? Kidney360 3:1991–1993. https://doi.org/10.34067/KID.0005722022

Gravel CA, Krewski D, Mattison DR et al (2023) Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis. Br J Clin Pharmacol 89:2430–2445. https://doi.org/10.1111/BCP.15711

Article  PubMed  CAS  Google Scholar 

Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384. https://doi.org/10.1016/S2213-8587(13)70208-0

Article  PubMed  CAS  Google Scholar 

Cherney DZI, Ferrannini E, Umpierrez GE et al (2021) Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab 23:2632–2642. https://doi.org/10.1111/DOM.14513

Article  PubMed  CAS  Google Scholar 

Cherney DZI, Ferrannini E, Umpierrez GE et al (2023) Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes Obes Metab 25:1646–1657. https://doi.org/10.1111/DOM.15019

Article  PubMed  CAS  Google Scholar 

Chertow GM, Vart P, Jongs N et al (2021) Effects of Dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 32:2352–2361. https://doi.org/10.1681/ASN.2021020167